Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Part A
- 1st Edition, Volume 165 - June 4, 2025
- Latest edition
- Editors: Arun Kumar Singh, Neeraj Mishra, Sumel Ashique, Pranav Kumar Prabhakar
- Language: English
Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy, Volume 165 in the Advances in Immunology series, presents current developments and comprehensive reviews in DN… Read more
Description
Description
Other chapters cover mRNA-Based Cancer Vaccines: A Novel Approach to Melanoma Treatment, Therapeutic mRNAs for cancer immunotherapy: from structure to delivery, Harnessing the immune system: Insights into cancer vaccines, Lipid Nanoparticle-Mediated mRNA Delivery in Cancer Immunotherapy, Immunotherapy Perspectives in the Era of B-Cell Editing in Cancer Treatment, Personalized Precision: Revolutionizing Cancer Treatment with mRNA-Based Vaccines in Melanoma Therapy, Revolutionizing Cancer Treatment: Exploring Novel Immunotherapeutics, Checkpoints, bispecifics, and Vaccines in Development, and more.
Key features
Key features
- Presents current developments and comprehensive reviews in immunology
- Provides the latest in a longstanding and respected serial on the subject matter
- Focuses on recent advances in the field of immunology
Readership
Readership
Table of contents
Table of contents
1. DNA and mRNA vaccines: Significant therapeutic approach against cancer management
Aniruddha Sen, Vijay Singh, Sumel Ashique, Jagriti, Sombuddha Biswas, Anas Islam,
Iman Ehsan, and Naheed Mojgani
2. Nucleic acid delivery as a therapeutic approach for cancer immunotherapy
Kashish Wilson, Garima, and Meenakshi Dhanawat
3. Plasmid DNA and mRNA Delivery: Approaches and Challenges
Arun Kumar Singh, Karan Goel, and Meenakshi Dhanawat
4. Viral & non-viral delivery of mRNA against cancer
Ece Guler, Humeyra Betul Yekeler, Muhammet Emin Cam, and Burcu Uner
5. Progress in modifying and elivering mRNA therapies for cancer immunotherapy
Karan Goel, Isha Chawla, Garima, Meenakshi Dhanawat, and Pramila Chaubey
6. mRNA-based cancer vaccines: A novel approach to melanoma treatment
Pranav Kumar Prabhakar, Tarun Kumar, Upadhyaya, and
Sanjeev Kumar Sahu
7. Therapeutic mRNAs for cancer immunotherapy: From structure to delivery
Monika Vishwakarma, Wasim Akram, and Tanweer Haider
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 165
- Published: June 18, 2025
- Language: English
About the editors
About the editors
AS
Arun Kumar Singh
Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at the University School of Pharmaceutical Sciences, Rayat Bahra University, Sahauran, India. His research interests include nano-formulation, cancer biology, and neuroscience, alongside digital and computational approaches such as machine learning, artificial intelligence, big data analytics, blockchain, and the Internet of Things. He has contributed academic books, book chapters, and review articles in pharmaceutical sciences and healthcare technology, with a focus on interdisciplinary approaches that integrate pharmaceutical research with emerging digital technologies.
NM
Neeraj Mishra
Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, India. His academic work focuses on novel drug delivery systems, including localized, targeted, and controlled delivery approaches using nanocarrier and microparticle-based technologies. His research interests encompass therapies for cancer and neurodegenerative disorders, and he has extensive experience in teaching, research supervision, and scholarly publishing. He has also contributed to innovation in pharmaceutical sciences through intellectual property development and collaborative academic activities. Through his research and educational initiatives, he supports the advancement of drug delivery strategies and pharmaceutical research.
SA
Sumel Ashique
Dr. Sumel Ashique has been working as an assistant professor at the Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, West Bengal, India. He has 5 years of teaching experience. He has achieved 100+ publications in international and national accredited reputed journals. He has expertise in drug delivery, nanotechnology, and targeted treatment strategies. Recently, he was honored to be in the World’s Top 2% Scientists by prestigious Stanford University, CA, United States, and Elsevier in 2025.
PP
Pranav Kumar Prabhakar
Pranav Kumar Prabhakar is Professor and Head of the Department of Biotechnology, School of Engineering and Technology, Nagaland University, Kohima, India. His research focuses on understanding molecular mechanisms involved in metabolic disorders, particularly diabetes, and on developing strategies for oral insulin delivery using natural products and biotechnology-based approaches. He is actively involved in research, academic mentoring, peer review, and editorial activities within the biomedical and biotechnology fields. His professional interests include translational research, signaling pathways associated with metabolic diseases, and the application of biotechnology to improve therapeutic outcomes. He contributes to scientific and academic initiatives that support advancements in biotechnology and healthcare research.